関連する実験動画
Updated: Aug 10, 2026

06:11
Culturing Primary Rat Inner Medullary Collecting Duct Cells
Published on: June 21, 2013
カプトプリル (SQ 14225) は,バソプレシンが欠けているラットの飲酒とアルドステロンを抑制します
Nature
|October 18, 1979
まとめ
糖尿病不発症 (DI) のラットでは,アンジオテンシンIIを阻害することで,飲酒量が減少した. これは,アンジオテンシンII濃度の上昇がDIの過剰な渇望に寄与し,水分バランスに影響することを示唆しています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 生理学 生理学とは
- ネフロロジーはネフロロジーを用います.
背景:
- アンジオテンシンII (Ang II) は渇きを刺激する (dipsogenic),バソプレシン (antidiuretic hormone,ADH) は水分泌を調節する.
- AngIIとADHは,哺乳類の水の恒常性を維持するために非常に重要です.
- 遺伝性糖尿病不発症 (DI),ADHが欠けているブラトレボロラットは,水の代謝を研究するためのモデルとして機能します.
研究 の 目的:
- DIラットで観察されたポリディプシアにおけるAng IIの役割を調査する.
- DIラットの水分摂取量とホルモンプロフィールに対するAng II合成を阻害する効果を決定する.
主な方法:
- DI Brattleboroのラットは,アンジオテンシン変換酵素 (ACE) の阻害剤であるカプトプリル (SQ 14225) を投与した.
- 飲酒量,プラズマアルドステロン,プラズマレニン活性などを測定した.
- ACE阻害に対する反応として,ホルモン変化と水位バランスを評価した.
主要な成果:
- カプトプリル投与は,DIラットにおける飲酒率を著しく低下させた.
- 6日間の治療の後,周回性プラズマアルドステロン濃度が低下し,高カリミアと一致しました.
- プラズマレニン活性とAng II濃度の上昇は,未治療のDIラットで観察されました.
結論:
- 糖尿病不発症に関連したポリディプシアは,部分的には血レニン活性とAng IIレベルが上昇したためです.
- DI Brattleboroラットの観察されたハイポアルドステロニズムには,組織特異のステロイド代謝と腎上皮質の感受性の変化が影響している可能性があります.
- これらの発見は,特にADH欠乏状態において,水平衡の調節におけるホルモンの複雑な相互作用を強調しています.
関連する概念動画
Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

